Literature DB >> 10353882

Effect of human immunodeficiency virus type 1 on intracellular activation and superoxide production by neutrophils.

J F Muñoz1, S Salmen, L R Berrueta, M P Carlos, J A Cova, J H Donis, M R Hernández, J V Torres.   

Abstract

The immunopathogenesis of AIDS is associated with the development of opportunistic infections by intracellular pathogens that can invade and reproduce freely because of impaired cellular functions. Neutrophils from asymptomatic human immunodeficiency virus (HIV) type 1-infected persons and from symptomatic patients with AIDS were found to retain normal phagocytosis activity while producing significantly less superoxide than neutrophils from HIV-1-negative subjects, when stimulated through Fc receptors or protein kinase C. After priming with a synthetic HIV-1 envelope peptide and stimulation via the Fc receptor, the neutrophils from HIV-1-negative controls had suppressed superoxide production, reduced phosphorylation of two unidentified cellular proteins, and increased expression of a third phosphoprotein. These results suggest that HIV-1 can produce direct functional damage of neutrophils through binding of envelope components to the cell membrane.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10353882     DOI: 10.1086/314821

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

Review 1.  Phagocytic activity in human immunodeficiency virus type 1 infection.

Authors:  Agostino Pugliese; Valerio Vidotto; Tiziana Beltramo; Donato Torre
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

2.  Mechanisms of neutrophil death in human immunodeficiency virus-infected patients: role of reactive oxygen species, caspases and map kinase pathways.

Authors:  S Salmen; H Montes; A Soyano; D Hernández; L Berrueta
Journal:  Clin Exp Immunol       Date:  2007-10-22       Impact factor: 4.330

3.  Increased Fas-mediated apoptosis in polymorphonuclear cells from HIV-infected patients.

Authors:  S Salmen; G Terán; L Borges; L Goncalves; B Albarrán; H Urdaneta; H Montes; L Berrueta
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

4.  A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils.

Authors:  Mark Duval; Marshall R Posner; Lisa A Cavacini
Journal:  J Virol       Date:  2008-02-13       Impact factor: 5.103

5.  CD8+ T cells but not polymorphonuclear leukocytes are required to limit chronic oral carriage of Candida albicans in transgenic mice expressing human immunodeficiency virus type 1.

Authors:  Miriam Marquis; Daniel Lewandowski; Véronique Dugas; Francine Aumont; Serge Sénéchal; Paul Jolicoeur; Zaher Hanna; Louis de Repentigny
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

Review 6.  Sphingolipids as Regulators of the Phagocytic Response to Fungal Infections.

Authors:  Arielle M Bryan; Maurizio Del Poeta; Chiara Luberto
Journal:  Mediators Inflamm       Date:  2015-11-25       Impact factor: 4.711

7.  Effect of GSTM1-Polymorphism on Disease Progression and Oxidative Stress in HIV Infection: Modulation by HIV/HCV Co-Infection and Alcohol Consumption.

Authors:  Mary Parsons; Adriana Campa; Shenghan Lai; Yinghui Li; Janet Diaz Martinez; Jorge Murillo; Pedro Greer; Sabrina Sales Martinez; Marianna K Baum
Journal:  J AIDS Clin Res       Date:  2013-08-31

8.  Neutrophil Effector Functions Are Not Impaired in Duffy Antigen Receptor for Chemokines (DARC)-Null Black South Africans.

Authors:  Kewreshini K Naidoo; Ayanda Ngubane; Pedzisai Gaza; Amber Moodley; Thumbi Ndung'u; Christina F Thobakgale
Journal:  Front Immunol       Date:  2019-03-26       Impact factor: 7.561

Review 9.  Animal Models of Cryptococcus neoformans in Identifying Immune Parameters Associated With Primary Infection and Reactivation of Latent Infection.

Authors:  Tyler G Normile; Arielle M Bryan; Maurizio Del Poeta
Journal:  Front Immunol       Date:  2020-09-15       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.